Premium
Efficacy and safety of ultrasound‐guided radiofrequency ablation of hyperplastic parathyroid gland for secondary hyperparathyroidism associated with chronic kidney disease
Author(s) -
Peng Chengzhong,
Zhang Zhengxian,
Liu Jibin,
Chen Hongyu,
Tu Xiao,
Hu Rihong,
Ni Jun,
Weng Ning,
Pang Haisu,
Xue Zhengmei
Publication year - 2017
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24657
Subject(s) - medicine , secondary hyperparathyroidism , ablation , parathyroid gland , parathyroid hormone , radiofrequency ablation , urology , kidney disease , hyperparathyroidism , ultrasound , endocrinology , calcium , radiology
Background The purpose of this study was to determine if ultrasound‐guided radiofrequency ablation (RFA) of hyperplastic parathyroid glands could be used to treat secondary hyperparathyroidism (HPT) in patients with chronic kidney disease. Methods RFA of the hyperplastic parathyroid glands was performed in 34 patients with secondary HPT. Intact parathyroid hormone (iPTH), calcium, and phosphorus were measured. The outcome was based on the ablation extent (ie, 4, 3, and 1–2 glands). Results The iPTH, calcium, and phosphorus levels decreased in all groups after RFA. One year after ablation, these parameters remained significantly lower in the 4‐gland ablation group compared with the 3‐gland and 1 to 2‐gland groups. The same tendency was observed for the symptom score. The iPTH levels of <272 pg/mL on the day after ablation was the best predictor for maintaining parathyroid hormone (PTH) levels in a reasonable range 1 year after ablation. Conclusions RFA of hyperplastic parathyroid glands for treating secondary HPT is feasible in selected patients. © 2016 Wiley Periodicals, Inc. Head Neck 39: 564–571, 2017